logo
Plus   Neg
Share
Email

Amphenol Posts Q1 Profit Of $126.56 Mln - Quick Facts

Amphenol Corp. (APH) reported net income attributable to the company of $126.56 million or $0.77 per share for the first quarter compared to $127.96 million or $0.72 per share reported a year earlier.

Net sales for the three-month period advanced to $981.6 million from $940.59 milion in the prior year. The company noted that currency translation had the effect of decreasing sales by around $4 million in the first quarter of 2012 compared to the 2011 period.

Analysts polled by Thomson Reuters expected the company to earn $0.76 per share on revenues of $972.14 million for the quarter. Analysts' estimates typically exclude special items.

Amphenol president and chief executive officer, Adam Norwitt, stated, "We expect Q2 2012 revenues in the range of $1.040 billion to $1.055 billion and diluted EPS in the range of $.82 to $.85. For the year 2012, we now expect to achieve revenues and diluted EPS in the range of $4.105 billion to $4.190 billion and $3.30 to $3.38, respectively, an increase of 4% to 6% and 8% to 11% over 2011 revenues and diluted EPS (excluding 2011 one-time items), respectively. This compares to prior full year 2012 guidance for revenues and diluted EPS in the range of $4.050 billion to $4.150 billion and $3.23 to $3.34, respectively."

Analysts expect the company to earn $0.83 per share on revenues of $1.03 billion for the second quarter.

Also, analysts expect the company to report earnings of $3.33 per share on revenues of $4.16 billion for the year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
An administrative law judge has ruled that Minnesota regulators should approve Enbridge Inc.'s proposal to replace its aging Line 3 crude oil pipeline only if the company follows the existing route and not its preferred route. Enbridge has applied to replace its Line 3 pipeline from Alberta with new pipe along its existing route. In Minnesota, the planned route deviates from the existing route. CLICK HERE to see America's 10 Best-Selling Drugs Despite high drug costs, most of the top-selling drugs saw sales gains in 2017 compared to the prior year. A large number of the best-selling drugs are primarily for the treatment and management of cancer, diabetes, inflammatory disorders, and HIV... Most Americans have access to health care, though costs and services vary from state to state. However, higher costs do not necessarily translate into better results. The U.S. continues to be outperformed by other wealthy nations on several measures like life expectancy, disease burden and health...
Follow RTT